Analyzing Metastat (OTCMKTS:MTST) and Haleon (NYSE:HLN)

Haleon (NYSE:HLN) and Metastat (OTCMKTS:MTST) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Institutional and Insider Ownership

6.7% of Haleon shares are owned by institutional investors. 8.5% of Metastat shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Haleon has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, Metastat has a beta of 291.17, indicating that its share price is 29,017% more volatile than the S&P 500.

Valuation and Earnings

This table compares Haleon and Metastat”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haleon	$14.54 billion	3.06	$2.20 billion	$0.39	25.63
Metastat	N/A	N/A	N/A	N/A	N/A

Haleon has higher revenue and earnings than Metastat.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Haleon and Metastat, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haleon	1	2	4	1	2.63
Metastat	0	0	0	0	0.00

Haleon currently has a consensus price target of $12.33, suggesting a potential upside of 23.31%. Given Haleon’s stronger consensus rating and higher possible upside, research analysts plainly believe Haleon is more favorable than Metastat.

Profitability

This table compares Haleon and Metastat’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Haleon	N/A	N/A	N/A
Metastat	N/A	N/A	N/A

Summary

Haleon beats Metastat on 6 of the 8 factors compared between the two stocks.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

About Metastat

MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company’s therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.